Link Pharma Chem Limited has submitted its quarterly confirmation certificate under SEBI Depositories Regulations to BSE Limited, maintaining compliance with regulatory requirements for the quarter ended March 31, 2026.

Regulatory Filing Details

The company filed the confirmation certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on April 8, 2026. The certificate was originally issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's registrar and share transfer agent.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026 were properly processed according to regulatory requirements. The registrar verified that:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed

Company Information

Link Pharma Chem Limited operates from its registered office at Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara, Gujarat. The company holds ISO-9001:2015 and ISO-14001:2015 certifications and is incorporated under CIN: L24230GJ1984PLC007540.

The filing was signed by Komal Bhojwani, Company Secretary and Compliance Officer (Membership No.: A65594), ensuring proper corporate governance and regulatory compliance procedures are maintained.

Link Pharma Chem Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, demonstrating a strong recovery from previous year losses. The Board of Directors approved these results during their meeting held on February 14, 2026, marking a significant turnaround in the company's financial performance.

Quarterly Performance Shows Strong Recovery

The company's Q3FY26 performance reflects a remarkable improvement across key financial metrics. Link Pharma Chem reported a profit of ₹6.82 lakhs for the quarter ended December 31, 2025, compared to a loss of ₹66.71 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Demonstrates Sustained Growth

For the nine months ended December 31, 2025, Link Pharma Chem achieved a profit of ₹28.55 lakhs compared to a loss of ₹67.71 lakhs in the corresponding period of the previous year. Revenue from operations increased by 9.78% to ₹2,084.27 lakhs from ₹1,898.68 lakhs in the previous year.

Operational Efficiency and Cost Management

The company's improved performance can be attributed to better operational efficiency and cost management. Total expenses for Q3FY26 were ₹643.05 lakhs compared to ₹567.17 lakhs in Q3FY25. Key expense components included cost of materials consumed at ₹324.11 lakhs, employee benefits expense of ₹160.27 lakhs, and other expenses totaling ₹124.21 lakhs.

Corporate Governance and Compliance

The financial results were reviewed by statutory auditors CNK & Associates LLP and recommended by the Audit Committee before Board approval. The company operates under a single business segment of "Manufacture and Sale of Chemicals" and maintains its paid-up equity share capital at ₹444.06 lakhs with shares of face value ₹10 each.

Link Pharma Chem Limited's Q3FY26 results demonstrate the company's successful turnaround strategy, with sustained profitability and revenue growth indicating improved operational performance and market positioning in the chemicals manufacturing sector.